{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:03:57Z","timestamp":1771542237178,"version":"3.50.1"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2014,3,19]],"date-time":"2014-03-19T00:00:00Z","timestamp":1395187200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0091545","type":"journal-article","created":{"date-parts":[[2014,3,20]],"date-time":"2014-03-20T02:47:00Z","timestamp":1395283620000},"page":"e91545","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":46,"title":["An Eight-Year Clinic Experience with Clozapine Use in a Parkinson\u2019s Disease Clinic Setting"],"prefix":"10.1371","volume":"9","author":[{"given":"Nawaz","family":"Hack","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah M.","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin H.","family":"Monari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umer","family":"Akbar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Hardwick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramon L.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene A.","family":"Malaty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Romrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aparna A. Wagle.","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus","family":"McFarland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert E.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Okun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,3,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1212\/01.wnl.0000341769.50075.bb","article-title":"Incidence and remaining lifetime risk of Parkinson disease in advanced age","volume":"72","author":"JA Driver","year":"2009","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","article-title":"Clozapine in drug induced psychosis in Parkinson&apos;s disease: a randomised, placebo controlled study with open follow up","volume":"75","author":"P Pollak","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.wnf.0000136891.17006.ec","article-title":"Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis","volume":"27","author":"L Morgante","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.WNF.0000236769.31279.19","article-title":"Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson&apos;s disease psychosis","volume":"29","author":"D Merims","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"ref5","first-page":"3","article-title":"Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry","volume":"59","author":"G Honigfeld","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3109\/10401239909147063","article-title":"Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson&apos;s disease","volume":"11","author":"MM Menza","year":"1999","journal-title":"Ann Clin Psychiatry"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/0897190011426556","article-title":"Atypical antipsychotic drugs in the treatment of Parkinson&apos;s disease","volume":"24","author":"JH Friedman","year":"2011","journal-title":"J Pharm Pract"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/mds.23884","article-title":"The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson&apos;s disease","volume":"26","author":"K Seppi","year":"2011","journal-title":"Mov Disord"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/WNF.0b013e31824d5115","article-title":"Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial","volume":"35","author":"L Pintor","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archneurol.2011.139","article-title":"Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis","volume":"68","author":"D Weintraub","year":"2011","journal-title":"Arch Neurol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4103\/0976-500X.114596","article-title":"Metabolic syndrome in schizophrenia: Differences between antipsychotic-na\u00efve and treated patients","volume":"4","author":"RK Chadda","year":"2013","journal-title":"J Pharmacol Pharmacother"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.4088\/JCP.v66n0901","article-title":"Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics","volume":"66","author":"R Liperoti","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.3949\/ccjm.79.s2a.03","article-title":"Nonmotor complications of Parkinson disease","volume":"79","author":"HH Fernandez","year":"2012","journal-title":"Cleve Clin J Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1155\/2013\/645429","article-title":"Parkinson disease psychosis: Update","volume":"27","author":"JH Friedman","year":"2013","journal-title":"Behav Neurol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00702-013-0994-0","article-title":"The practical management of cognitive impairment and psychosis in the older Parkinson&apos;s disease patient","volume":"120","author":"JV Hindle","year":"2013","journal-title":"J Neural Transm"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/S1353-8020(09)70846-6","article-title":"Hallucinations and psychosis in Parkinson&apos;s disease","volume":"15","author":"JM Rabey","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1089\/cap.2011.0136","article-title":"Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia","volume":"23","author":"KN Maher","year":"2013","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/mds.22553","article-title":"Transient amantadine-induced musical hallucinations in a patient with Parkinson&apos;s disease","volume":"25","author":"FeA Gondim","year":"2010","journal-title":"Mov Disord"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.parkreldis.2010.06.010","article-title":"Isolated delusional syndrome in Parkinson&apos;s Disease","volume":"16","author":"N Stefanis","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/ki.2008.464","article-title":"Altered mental status in a transplant patient. Amantadine toxicity","volume":"75","author":"LS Michalski","year":"2009","journal-title":"Kidney Int"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/jnnp.2008.152579","article-title":"When a Parkinson&apos;s disease patient starts to hallucinate","volume":"8","author":"W Poewe","year":"2008","journal-title":"Pract Neurol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.parkreldis.2008.08.005","article-title":"Plasma amantadine concentrations in patients with Parkinson&apos;s disease","volume":"15","author":"N Nishikawa","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1532-5415.1975.tb00187.x","article-title":"Visual hallucinations and delirium during treatment with amantadine (Symmetrel)","volume":"23","author":"JU Postma","year":"1975","journal-title":"J Am Geriatr Soc"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"680.e687","DOI":"10.1016\/j.genhosppsych.2013.03.023","article-title":"Delirium with manic and psychotic features associated with amantadine","volume":"35","author":"AD Neagoe","year":"2013","journal-title":"Gen Hosp Psychiatry"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1176\/appi.ajp.2008.08081228","article-title":"Amantadine-induced psychosis in a young healthy patient","volume":"165","author":"EJ Smith","year":"2008","journal-title":"Am J Psychiatry"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1212\/WNL.51.3.811","article-title":"Early dopaminergic drug-induced hallucinations in parkinsonian patients","volume":"51","author":"CG Goetz","year":"1998","journal-title":"Neurology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.parkreldis.2013.04.001","article-title":"Motor and non-motor symptoms of 1453 patients with Parkinson&apos;s disease: prevalence and risks","volume":"19","author":"A Yoritaka","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.parkreldis.2013.06.006","article-title":"High rates and the risk factors for emergency room visits and hospitalization in Parkinson&apos;s disease","volume":"19","author":"A Hassan","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/0004867411433210","article-title":"Transitioning patients taking clozapine from the public to private\/GP shared-care setting: barriers and criteria","volume":"46","author":"SL Filia","year":"2012","journal-title":"Aust N Z J Psychiatry"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/ana.23697","article-title":"Substantia nigra depigmentation and exposure to encephalitis lethargica","volume":"72","author":"N Hack","year":"2012","journal-title":"Ann Neurol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.parkreldis.2012.07.008","article-title":"Long-duration Parkinson&apos;s disease: role of lateralization of motor features","volume":"19","author":"RP Munhoz","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/RLU.0b013e3182873511","article-title":"Brain regions associated with cognitive impairment in patients with Parkinson disease: quantitative analysis of cerebral blood flow using 123I iodoamphetamine SPECT","volume":"38","author":"N Hattori","year":"2013","journal-title":"Clin Nucl Med"},{"key":"ref33","article-title":"Determining when to start levodopa\/carbidopa\/entacapone treatment in Spanish patients with Parkinson&apos;s disease","author":"P Mart\u00ednez-Mart\u00edn","year":"2013","journal-title":"Neurologia"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/jgs.12027","article-title":"Motor profile and drug treatment of nursing home residents with Parkinson&apos;s disease","volume":"60","author":"NJ Weerkamp","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.parkreldis.2012.06.014","article-title":"What are the issues facing Parkinson&apos;s disease patients at ten years of disease and beyond? Data from the NPF-QII study","volume":"18","author":"A Hassan","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1212\/01.WNL.0000068010.82167.CF","article-title":"Longitudinal outcome of Parkinson&apos;s disease patients with psychosis","volume":"60","author":"SA Factor","year":"2003","journal-title":"Neurology"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","article-title":"Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study","volume":"62","author":"F Durif","year":"2004","journal-title":"Neurology"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1212\/WNL.55.6.789","article-title":"Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients","volume":"55","author":"CG Goetz","year":"2000","journal-title":"Neurology"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1176\/jnp.12.3.364","article-title":"Clozapine and risperidone treatment of psychosis in Parkinson&apos;s disease","volume":"12","author":"T Ellis","year":"2000","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson&apos;s disease","volume":"340","year":"1999","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1212\/WNL.40.5.832","article-title":"Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis","volume":"40","author":"EC Wolters","year":"1990","journal-title":"Neurology"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.sapharm.2010.03.006","article-title":"New Zealand community pharmacists&apos; views of their roles in meeting medicine-related needs for people with mental illness","volume":"7","author":"K Crump","year":"2011","journal-title":"Res Social Adm Pharm"},{"key":"ref43","first-page":"280","article-title":"Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson&apos;s disease","volume":"21","author":"G Friedberg","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/1531-8257(200101)16:1<135::AID-MDS1006>3.0.CO;2-Q","article-title":"Clozapine for the treatment of drug-induced psychosis in Parkinson&apos;s disease: results of the 12 week open label extension in the PSYCLOPS trial","volume":"16","author":"SA Factor","year":"2001","journal-title":"Mov Disord"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/mds.870130302","article-title":"Clozapine use in Parkinson&apos;s disease: a retrospective analysis of a large multicentered clinical experience","volume":"13","author":"RM Trosch","year":"1998","journal-title":"Mov Disord"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1517\/14656566.2011.587122","article-title":"An update expert opinion on management and research strategies in Parkinson&apos;s disease psychosis","volume":"12","author":"JG Goldman","year":"2011","journal-title":"Expert Opin Pharmacother"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0091545","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T02:37:33Z","timestamp":1540348653000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0091545"}},"subtitle":[],"editor":[{"given":"Pedro","family":"Gonzalez-Alegre","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,3,19]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,3,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0091545","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,19]]}}}